Table 1. Clinical characteristics and SVR analysis of Taiwanese patients with chronic HCV infection.
| Clinical characteristic | Total (N=728) | SVR positive (N=559) | SVR negative (N=169) | P-value |
|---|---|---|---|---|
| Age on IFN therapy | 51.2±10.4 | 50.1±10.5 | 54.8±9.3 | <0.001* |
| Male | 444 (61.0%) | 361 (64.6%) | 83 (49.1%) | <0.001* |
| Liver cirrhosis | 246 (33.8%) | 155 (27.7%) | 91 (53.8%) | <0.001* |
| HCV genotype: | ||||
| Genotype 1 | 424 (58.2%) | 281 (50.3%) | 143 (84.6%) | <0.001* |
| Non-genotype 1 | 304 (41.8%) | 278 (49.7%) | 26 (15.4%) | |
| HCV RNA ≥0.4 miu | 318 (43.7%) | 204 (36.5%) | 114 (67.5%) | <0.001* |
| BMI ≥27 kg m–2 | 146 (20.1%) | 106 (19.0%) | 40 (23.7%) | 0.181 |
| Adherence | 483 (66.3%) | 386 (69.1%) | 39 (23.1%) | 0.005* |
| Regimen | ||||
| INTRON+RBV | 126 (17.3%) | 98 (17.5%) | 28 (16.6%) | 0.772 |
| PEG-IFN+RBV | 602 (82.7%) | 461 (82.5%) | 141 (83.4%) | |
Abbreviations: BMI, body mass index; HCV, hepatitis C virus; PEG IFN, pegylated interferon; RBV, ribavirin; SVR, sustained virological response.
*P<0.05.